These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 14624694)

  • 1. Importance of nondrug costs of intravenous antibiotic therapy.
    van Zanten AR; Engelfriet PM; van Dillen K; van Veen M; Nuijten MJ; Polderman KH
    Crit Care; 2003 Dec; 7(6):R184-90. PubMed ID: 14624694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
    Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
    Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential for cost-savings in the care of hospitalized low-risk community-acquired pneumonia patients in China.
    Zhou QT; He B; Zhu H
    Value Health; 2009; 12(1):40-6. PubMed ID: 18637052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia.
    Cortoos PJ; Gilissen C; Laekeman G; Peetermans WE; Leenaers H; Vandorpe L; Simoens S
    Scand J Infect Dis; 2013 Mar; 45(3):219-26. PubMed ID: 23113827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nondrug costs of therapy in acute care--are they important?
    Edbrooke DL; Bourne RS
    Crit Care; 2003 Dec; 7(6):420-1. PubMed ID: 14624680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs associated with shorter duration of antibiotic therapy in hospitalized patients with mild-to-moderate severe community-acquired pneumonia.
    Opmeer BC; El Moussaoui R; Bossuyt PM; Speelman P; Prins JM; de Borgie CA
    J Antimicrob Chemother; 2007 Nov; 60(5):1131-6. PubMed ID: 17827142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A pharmacoeconomic study of in-hospital treatment against community-acquired pneumonia].
    Bermejo Vicedo T; Torralba Arranz A; Hidalgo Correas FJ; Millán Santos I; Rodríguez Morradan B
    Farm Hosp; 2004; 28(1):29-35. PubMed ID: 15012176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic utilization and cost analysis in hospitalized patients with community-acquired pneumonia.
    Stein GE; Mantz SL
    Hosp Pharm; 1995 Feb; 30(2):132-4, 137. PubMed ID: 10140526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.
    Houck PM; Bratzler DW; Nsa W; Ma A; Bartlett JG
    Arch Intern Med; 2004 Mar; 164(6):637-44. PubMed ID: 15037492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuity of antibiotic therapy in patients admitted from the emergency department.
    Shah MN; Schmit J; Croley WC; Meltzer D
    Ann Emerg Med; 2003 Jul; 42(1):117-23. PubMed ID: 12827131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of community-acquired pneumonia by trained family general practitioners.
    Potena A; Simoni M; Cellini M; Cartabellotta A; Ballerin L; Piattella M; Putinati S
    Int J Tuberc Lung Dis; 2008 Jan; 12(1):19-25. PubMed ID: 18173872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis.
    Marras TK; Nopmaneejumruslers C; Chan CK
    Am J Med; 2004 Mar; 116(6):385-93. PubMed ID: 15006587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Errors in preparation and administration of intravenous medications in the intensive care unit of a teaching hospital: an observational study.
    Fahimi F; Ariapanah P; Faizi M; Shafaghi B; Namdar R; Ardakani MT
    Aust Crit Care; 2008 May; 21(2):110-6. PubMed ID: 18387813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost comparison of intravenous antibiotic administration.
    Plumridge RJ
    Med J Aust; 1990 Nov; 153(9):516-8. PubMed ID: 2233472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia.
    Davis SL; Delgado G; McKinnon PS
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S136-43. PubMed ID: 15942880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of emergency department crowding on time to antibiotics in patients admitted with community-acquired pneumonia.
    Fee C; Weber EJ; Maak CA; Bacchetti P
    Ann Emerg Med; 2007 Nov; 50(5):501-9, 509.e1. PubMed ID: 17913300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of treating lower respiratory tract infections.
    Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA
    Am J Manag Care; 2008 Apr; 14(4):190-6. PubMed ID: 18402511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [National multicenter survey: the use of intravenous antimicrobial agents].
    Gutiérrez Zufiaurre MN; García-Rodríguez JA
    Rev Esp Quimioter; 2006 Dec; 19(4):349-56. PubMed ID: 17235404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.